Neither of the primary tumor lines developed in this study were capable of producing tumor xenografts and so this study relied on utilizing the SMARCB1‐deficient rhabdoid cell line G401 as a substitute for an actual RMC cell line in its in vivo studies.20 This evidence concerns the gene SMARCB1 and neoplasm.